. Author manuscript; available in PMC: 2021 Dec 22.

Published in final edited form as: Mater Sci Eng C Mater Biol Appl. 2020 Aug 27;119:111460. doi: 10.1016/j.msec.2020.111460

Table 1.

IC₅₀ to 2D and 3D model.

Cell line	RT4		PDX

Treatments	2D	3D	2D	3D
Glycoalkaloidic extract (GE) (μg/mL)	10.12 ± 0.23	21.81 ± 6.67^*	38.21 ± 9.67	54.43 ± 16.22^**
Cisplatin (cDDP) (μM)	18.13 ± 0.37	47.76 ± 10.4 ^***	40.22 ± 11.73	60.16 ± 13.32^***
GE (IC₂₅) + cDDP (μM)	8.43 ± 0.23	28.06 ± 6.89^**	32.65 ± 9.33	48.43 ± 8.33^**

Each data point was represented as mean ± SD (n = 4).

p < 0.05,

^**

p < 0.01,

^***

p < 0.001 versus respective 2D groups.